Join the Nexlizet group to help and get support from people like you.
Nexlizet News
U.S. FDA Approves Broad New Labels for Nexletol and Nexlizet to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) – Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for...
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s Nexletol (bempedoic acid) Tablet and Nexlizet (bempedoic acid and ezetimibe) Tablet
Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA...
FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol
ANN ARBOR, Mich., Feb. 26, 2020 (GLOBE NEWSWIRE) – Esperion (NASDAQ:ESPR) today announced that the U.S. Food and Drug Administration (FDA) approved Nexlizet (bempedoic acid and ezetimibe) tablet, an...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
High Cholesterol, High Cholesterol - Familial Heterozygous, Cardiovascular Risk Reduction